Autonomix Medical, Inc. (NASDAQ: AMIX) has announced results from a post-hoc exploratory subgroup analysis of its first-in-human proof-of-concept study (PoC 1) evaluating a targeted ablation therapy for severe pancreatic cancer pain. The study examined the safety and effectiveness of delivering transvascular energy to ablate problematic nerves. The subgroup analysis assessed patient-reported quality-of-life, symptoms, and functional outcomes using the EORTC QLQ-C30 scale across various patient groups, including those with different tumor stages and metastatic status. Results indicated improvements in symptom scores, functionality, and global quality of life at both 4-6 weeks and 3 months post-treatment, with all 3-month results exceeding the EORTC threshold for clinically meaningful change. These findings, along with previously reported pain reduction and opioid-free outcomes, will inform the design of Autonomix's planned U.S.-based multicenter clinical trial, scheduled to begin in 2026.